|
Ixico PLC on Monday hailed an ‘important’ contract win to further research into neurological disorder, Huntington’s Disease. The London-based medical research company, focused on analysing trial data using neuroscience imaging and biomarkers, said the deal, worth £3.5 million over four years, is with a global pharmaceutical company to provide imaging services for a phase 3 trial in the disease. ‘This is an important contract in terms of value and trial stage that further cements Icixo’s position in the field,’ said Ixico Chief Executive Bram Goorden. ‘I am greatly encouraged by biopharma’s increased commitment to invest in rare neurological diseases and optimistic this will lead to disease modifying solutions in the near future,’ Goorden added. Shares in Ixico rose 4.9% to 11.28 pence each in London on Monday morning. Copyright 2025 Alliance News Ltd. All Rights Reserved.
|
